Ticagrelor is a medicine used to prevent blood clots. It helps stop platelets from sticking together, which can reduce the risk of heart attack or stroke in certain people. It's often used after a heart attack or for other conditions that increase clot risk.
Every report comes from a Lived member, sent anonymously.
Have you tried Brilinta (Ticagrelor) for Acute Coronary Syndrome?
Ticagrelor, sold as Brilinta and also available as a generic, is a prescription antiplatelet medicine. It lowers the chance that platelets clump into a clot inside an artery, the event behind most heart attacks and many strokes. It is usually taken together with low-dose aspirin. Its main use follows an acute coronary syndrome (ACS), the umbrella term for a heart attack or unstable angina, when blood flow to part of the heart is suddenly blocked or reduced. After ACS, or in people who had a heart attack in the past, it lowers the risk of another heart attack, stroke and death from heart disease. In people who received a stent during that event, it also lowers the risk of a clot forming inside the stent. In the large trial behind its approval, it prevented more of these events over the first year than clopidogrel, an older medicine from the same family. Two other uses are narrower. Ticagrelor can lower the risk of a first heart attack or stroke in people with coronary artery disease who are at high risk of one; that benefit was shown mainly in people who also had type 2 diabetes. It is also given for up to a month after a minor ischemic stroke (a stroke caused by a blocked artery) or a high-risk transient ischemic attack (TIA, sometimes called a mini-stroke), to lower the chance of another stroke in the weeks that follow. In that trial, adding ticagrelor to aspirin for 30 days reduced stroke or death from about 6.5 in 100 people to 5.4 in 100.
Platelets are small blood cells that seal injuries by sticking together. When the inner lining of a narrowed artery in the heart or brain is damaged, platelets gather at the damaged spot and can build a clot large enough to block the artery. Activated platelets release a chemical signal called ADP, which recruits more platelets by attaching to a receptor on their surface called P2Y12. Ticagrelor blocks the P2Y12 receptor, so platelets respond less to that signal and are less likely to pile up into a clot. Its effect peaks about two hours after the first dose. The block is reversible, so the effect fades as the drug leaves the body, and platelet function is largely back to normal about five days after the last dose. That is why it is taken twice a day, and why pausing it before surgery takes several days. Like other blood thinners, it helps prevent new clots and stops existing ones from growing, but it does not dissolve a clot that has already formed.
Ticagrelor is a tablet taken twice a day, at around the same times each day, with or without food. After a heart attack, minor stroke or TIA, treatment usually starts with a larger first dose of 180 mg (two 90 mg tablets), followed by 90 mg twice daily. For people treated after a heart attack, the dose usually drops to 60 mg twice daily after the first year. The 60 mg dose is also the one used for coronary artery disease without a previous heart attack or stroke. After a minor stroke or TIA, treatment lasts up to 30 days. Ticagrelor is normally paired with a daily aspirin of 75 to 100 mg. Some people who have had a stent placed are later moved to ticagrelor alone, without aspirin, when their cardiologist judges that the risk of bleeding outweighs the extra protection against clots. If a dose is missed, take the next one at its usual time rather than doubling up. People who cannot swallow tablets can crush them, stir them into water and drink the mixture. The most important instruction is not to stop on your own. Stopping too early, especially in the months after a stent, raises the risk of a clot in the stent, a heart attack and death. If bleeding, a planned procedure or side effects make stopping seem necessary, talk with the prescriber first.
Bleeding is the main side effect, as with every antiplatelet medicine. Most of it is minor: bruising more easily, more frequent nosebleeds, and cuts that take longer to stop. Ticagrelor can also cause serious and occasionally fatal bleeding inside the body. Call the prescriber right away for pink, red or brown urine, red or black tarry stools, vomit that contains blood or looks like coffee grounds, or coughing up blood. Bleeding that is heavy and will not stop needs emergency care. Shortness of breath is the other side effect people notice, reported by roughly 14 to 21 in 100 people in clinical trials. It is usually mild to moderate, often fades with continued treatment, and lung function tests in a trial substudy did not show harm to the lungs. New or worsening shortness of breath should still be reported so the care team can check the cause rather than assume it is the drug. If it is intolerable, another antiplatelet medicine can be considered. Dizziness and nausea are also common. Less often, ticagrelor slows the heart rhythm or causes pauses in breathing during sleep. A slow or irregular heartbeat, or a partner noticing that your breathing stops and starts at night, should be raised with the care team promptly. Swelling of the face, lips, tongue or throat can signal an allergic reaction and needs immediate medical attention.
Ticagrelor should not be used by anyone who is currently bleeding, for example from a stomach ulcer, or who has ever had bleeding in the brain, because the risk of another brain bleed is high. It is not started in someone about to have urgent heart bypass surgery. It is avoided in severe liver disease, which can raise drug levels, and people with a slow heart rhythm not protected by a pacemaker need closer thought. Breastfeeding is not recommended while taking it. Human pregnancy data are limited, so anyone pregnant or planning pregnancy should discuss it with the prescriber. The aspirin dose matters. Ticagrelor is combined with low-dose aspirin, and in most cases aspirin should not exceed 100 mg a day. Check over-the-counter pain and cold products for hidden aspirin, and ask before using ibuprofen, naproxen or the herbal supplement St. John's wort. Ticagrelor is never taken together with another medicine of the same type, such as clopidogrel or prasugrel. Some medicines change how much ticagrelor reaches the blood. Drugs that strongly block the liver enzyme that clears it raise levels and the risk of bleeding and breathlessness; examples include the antifungals ketoconazole, itraconazole and voriconazole, the antibiotic clarithromycin, and HIV medicines such as ritonavir. Drugs that strongly speed up that enzyme can make ticagrelor ineffective; examples include rifampin (a tuberculosis antibiotic) and the seizure medicines phenytoin, carbamazepine and phenobarbital. Ticagrelor in turn raises levels of the cholesterol medicines simvastatin and lovastatin, which are kept at 40 mg a day or less, and of rosuvastatin. People taking digoxin, a heart rhythm medicine, need their digoxin levels checked when ticagrelor starts or changes. Opioid pain medicines given during a heart attack can delay its absorption. Ask about grapefruit as well. Tell every surgeon and dentist that you take ticagrelor, and have them talk with the prescriber before any procedure. For operations with a major bleeding risk, it is often paused five days beforehand and restarted as soon as bleeding is under control.
Ticagrelor works from the first dose, but nothing feels different when it is working. Its benefit is the heart attacks, stent clots and strokes that do not happen, so there is no symptom to tell you it is helping. Most people mainly notice easier bruising and, in some, shortness of breath in the early weeks. How long treatment lasts depends on why it was prescribed. After a minor stroke or TIA it is a short course of up to 30 days. After a heart attack, the standard plan is 90 mg twice daily for the first year, and some people then continue on the lower 60 mg dose for the longer term when their risk of another event is high and bleeding has not been a problem. The cardiologist weighs those two risks at follow-up visits, and may shorten treatment, switch to ticagrelor alone or change to another antiplatelet medicine. Because stopping early is risky after a stent, refills should not lapse, and any reason to pause, from a dental extraction to a bleeding problem, is best handled with the prescriber rather than by skipping doses.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Brilinta (Ticagrelor), what you've noticed, or ask the community a question.